Outcome of elective withdrawal of anti-tumour necrosis factor-α therapy in patients with Crohn's disease in established remission

Journal of Crohn's and Colitis

Volumn 11, Issue 12, 2017, Pages 1456-1462

  Brooks, A J ^a   Sebastian, S ^b   Cross, S S ^c   Robinson, K ^a   Warren, L ^d   Wright, A ^a   Marsh, A M ^a   Tsai, H ^b   Majeed, F ^d   McAlindon, M E ^a   Preston, C ^e   Hamlin, P J ^d   Lobo, A J ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b CASTLE HILL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^e BRADFORD ROYAL INFIRMARY   (United Kingdom)

Author keywords

Anti TNF therapy; Crohn's disease; Immunosuppression; Treatment withdrawal

Indexed keywords

CALGRANULIN; TUMOR NECROSIS FACTOR INHIBITOR; ADALIMUMAB; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR;

ADOLESCENT; ADULT; AGED; ANUS FISTULA; ARTICLE; CHILD; CLINICAL OUTCOME; CLINICAL TRIAL; COLON SURGERY; CROHN DISEASE; DISEASE ASSESSMENT; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; ENDOSCOPY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; REMISSION; RISK FACTOR; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COLON; COLONOSCOPY; DIAGNOSTIC IMAGING; FECES; ILEUM; MIDDLE AGED; RECURRENT DISEASE; TIME FACTOR; TREATMENT WITHDRAWAL; YOUNG ADULT;

ADALIMUMAB; ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; COLON; COLONOSCOPY; CROHN DISEASE; FECES; FEMALE; FOLLOW-UP STUDIES; HUMANS; ILEUM; INFLIXIMAB; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 85020249090     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2014.09.007     Document Type: Article

References (13)

1. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F. et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359 (9317) 1541-1549.
2. Hanauer S.B., Sandborn W.J., Rutgeerts P., Fedorak R.N., Lukas M., Macintosh D. et al. Human anti-tumor necrosis factor monocol-onal antibody (adalimumab) in Crohn's disease: the CLASSIC I trial. Gastroenterology 2006; 130 (2) 323-333.
3. Sandborn W.J., Hanauer S.B., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D.G. et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56 (9) 1232-1239.
4. Colombel J.F., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R. et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132 (1) 52-65.
5. Rutgeerts P., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F. et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126 (2) 402-413.
6. Louis E., Löfberg R., Reinisch W., Camez A., Yang M., Pollack P.F. et al. Adalimumab improves patient-related outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial. J Crohns Colitis 2013;7 (1) 34-43.
7. NICE technology appraisal guidance 187 Infliximab (review) and adalimumab for the treatment of Crohn's disease (including a review of technology appraisal guidance 40). www.nice.org.uk/guidance/ TA187. National Institute for Heath and Care Excellence. Issued: May 2010.
8. Louis E., Mary J.Y., Vernier-Massouille G., Grimaud J.C., Bouhnik Y., Laharie D. et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012;142 (1) 63-70.
9. Molnar T., Lakatos P.L., Farkas K., Nagy F., Szepes Z., Miheller P. et al. Predictors of relapse in patients with Crohn's disease in remission after 1year of biological therapy. Aliment Pharmacol Ther 2013;37 (2) 225-233.
10. Waugh A.W., Garg S., Matic K., Gramlich L., Wong C., Sadowski D.C. et al. Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. Aliment Pharmacol Ther 2010;32 (9) 1129-1134.
11. Panaccione R., Colombel J.F., Sandborn W.J., D'Haens G., Zhou Q., Pollack P.F. et al. Adalimumab maintains remission of Crohn's disease after up to 4years of treatment: data from CHARM and ADHERE. Aliment Pharmacol Ther 2013;38 (10) 1236-1247.
12. Blackmore L., Harris A. A prospective study of infliximab withdrawal after 12months of treatment in patients with Crohn's disease: how will NICE guidance affect patient care. Clin Med 2012;12 (3) 235-238.
13. D'Haens G., Ferrante M., Vermeire S., Baert F., Noman M., Moortgat L. et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012;18 (12) 2218-2224